Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first line therapy in subjects with metastatic CRC. - Hurwitz,H.; Fehrenbacher,L.; Cartwright,T. (Proc Am Soc Clin Oncol, 2003)